Quarterly ResultMay 6, 2026, 04:07 PM
Lyell Immunopharma Q1 Net Loss $24.2M; Phase 3 Dosing Commences
AI Summary
Lyell Immunopharma reported a net loss of $24.2 million for the first quarter ended March 31, 2026, a significant improvement from $52.2 million in the prior year. The company commenced patient dosing in its PiNACLE-H2H Phase 3 clinical trial for ronde-cel in second-line large B-cell lymphoma (LBCL) and expects additional data from the PiNACLE pivotal trial in third-line LBCL in H2 2026, with BLA submission in 2027. Lyell also closed the second $50 million tranche of its private placement, bringing its cash balance to $261 million, which is expected to fund operations into Q3 2027.
Key Highlights
- Lyell Immunopharma reported a Q1 2026 net loss of $24.2 million, down from $52.2 million in Q1 2025.
- Research and development expenses decreased to $36.6 million in Q1 2026 from $43.4 million in Q1 2025.
- General and administrative expenses decreased to $9.6 million in Q1 2026 from $14.0 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $261.0 million as of March 31, 2026.
- The company expects its cash runway to extend into Q3 2027.
- Patient dosing commenced in the PiNACLE-H2H Phase 3 trial for ronde-cel in February 2026.
- PiNACLE pivotal trial for ronde-cel expects additional data in H2 2026 and BLA submission in 2027.
- Closed the second $50 million tranche of its $100 million private placement at $25.61 per share.